International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 1 , Pages 24-33 , 1 September 2008

Subsequent Malignancies in Children Treated for Hodgkin's Disease: Associations With Gender and Radiation Dose

  • Louis S. Constine, M.D.

      Affiliations

    • Department of Radiation Oncology, James P. Wilmot Cancer Center at the University of Rochester, Rochester, NY
    • Department of Pediatrics, James P. Wilmot Cancer Center at the University of Rochester, Rochester, NY
    • Corresponding Author InformationReprint requests to: Louis S. Constine MD, Departments of Radiation Oncology and Pediatrics, University of Rochester Medical Center, 601 Elmwood Avenue Box 647, Rochester, NY 14642. Tel: (585) 275-5622; Fax: (585) 275-1531
    • ,
  • Nancy Tarbell, M.D.

      Affiliations

    • Department of Pediatric Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • ,
  • Melissa M. Hudson, M.D.

      Affiliations

    • Department of Hematology–Oncology, St. Jude Children's Research Hospital, Memphis, TN
    • ,
  • Cindy Schwartz, M.D.

      Affiliations

    • Department of Hematology–Oncology, The Johns Hopkins Hospital, Baltimore, MD
    • ,
  • Susan G. Fisher, Ph.D.

      Affiliations

    • Department of Community and Preventative Medicine, James P. Wilmot Cancer Center at the University of Rochester, Rochester, NY
    • ,
  • Ann G. Muhs, B.A.

      Affiliations

    • Department of Radiation Oncology, James P. Wilmot Cancer Center at the University of Rochester, Rochester, NY
    • ,
  • Swati K. Basu, M.B.B.S., M.P.H., PH.D.

      Affiliations

    • Department of Community and Preventative Medicine, James P. Wilmot Cancer Center at the University of Rochester, Rochester, NY
    • ,
  • Larry E. Kun, M.D.

      Affiliations

    • Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, TN
    • ,
  • Andrea Ng, M.D., M.P.H.

      Affiliations

    • Department of Radiation Oncology, Brigham & Women's Hospital, Boston, MA
    • ,
  • Peter Mauch, M.D.

      Affiliations

    • Department of Radiation Oncology, Brigham & Women's Hospital, Boston, MA
    • ,
  • Ajay Sandhu, M.D.

      Affiliations

    • Department of Radiation Oncology, University of California Medical Center–San Diego, San Diego, CA
    • ,
  • Eva Culakova, Ph.D.

      Affiliations

    • Department of Community and Preventative Medicine, James P. Wilmot Cancer Center at the University of Rochester, Rochester, NY
    • ,
  • Gary Lyman, M.D., M.P.H.

      Affiliations

    • Department of Medicine, Duke University Medical Center, Durham, NC
    • ,
  • Nancy Mendenhall, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Florida Medical Center, Gainesville, FL

Received 1 November 2007 ,Revised 2 April 2008 ,Accepted 8 April 2008.

References 

  1. Donaldson SS, Link MP. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol. 1987;5:742–749
  2. Hutchinson R, Fryer C, Davis P, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: Results of the Children's Cancer Group Phase III Trial. J Clin Oncol. 1998;16:897–906
  3. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol. 2000;18:1500–1507
  4. Nachman J, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765–3771
  5. Rühl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: An interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys. 2001;51:1209–1218
  6. Donaldson S, Hudson M, Lamborn K, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: Results of a prospective clinical trial. J Clin Oncol. 2002;20:3081–3087
  7. Bhatia S, Yasui Y, Robison L, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386–4394
  8. Metayer C, Lynch C, Clarke E, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol. 2000;18:2435–2443
  9. Sankila R, Garwicz J, Olsen H, et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: A population-based cohort study in five Nordic countries. J Clin Oncol. 1996;14:1442–1446
  10. Hudson M, Poquette C, Lee J, et al. Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol. 1998;16:3592–3600
  11. Abrahamsen JF, Andersen A, Hannisdal E, et al. Second malignancies after treatment of Hodgkin's disease: The influence of treatment, follow-up time, and age. J Clin Oncol. 1993;11:255–261
  12. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: A report from the International Database on Hodgkin's disease. Ann Oncol. 1992;3(Suppl 4):117–128
  13. Kaldor J, Day N, Clarke E, et al. Leukemia following Hodgkin's disease. N Eng J Med. 1990;322:7–13
  14. van Leeuwen F, Klokman W, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol. 1994;12:312–325
  15. van Leeuwen F, Klokman W, van't Veer M, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18:487–497
  16. Hancock S, Tucker M, Hoppe R. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 1993;85:25–31
  17. Boivin JF, Hutchison GB, Zauber AG, et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst. 1995;87:732–741
  18. Mauch P, Kalish L, Marcus K, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: Long-term analysis of risk factors and outcome. Blood. 1996;87:3625–3632
  19. Kaldor J, Day N, Band P, et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: An international collaborative study among cancer registries. Int J Cancer. 1987;39:571–585
  20. Tucker M, Coleman C, Cox R, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988;318:76–81
  21. Cellai E, Magini S, Masala G, et al. the risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: Analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. Int J Radiat Oncol Biol Phys. 2001;49:1327–1337
  22. Bhatia S, Robison L, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334:745–751
  23. Tarbell N, Gelber R, Weinstein H, et al. Gender differences in risk of second malignant tumours after Hodgkin's disease in childhood. Lancet. 1993;341:1428–1432
  24. Beaty O, Hudson M, Greenwald C, et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol. 1995;13:603–609
  25. Wolden S, Lamborn K, Cleary S, et al. Second cancers following pediatric Hodgkin's disease. J Clin Oncol. 1998;16:536–544
  26. Green D, Hyland A, Barcos M, et al. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol. 2000;18:1492–1499
  27. Neglia J, Friedman D, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. J Nat Cancer Inst. 2001;93:618–629
  28. Armstrong G, Sklar C, Hudson M, et al. Long-term health status among survivors of childhood cancer: Does gender matter?. J Clin Oncol. 2007;25:4477–4489
  29. Ng A, Bernardo M, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood. 2002;100:1989–1996
  30. Foss Abrahamsen A, Andersen A, Nome O, et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: The influence of treatment, age and follow-up time. Ann Oncol. 2002;13:1786–1791
  31. Dores G, Metayer C, Curtis R, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484–3494
  32. Travis L, Gospodarowicz M, Curtis R, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94:182–192
  33. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for hodgkin lymphoma. J Natl Cancer Inst. 2005;97:1428–1437
  34. Hill DA, Gilbert E, Dores GM, et al. Breast cancer risk following radiotherapy for hodgkin lymphoma: Modification by other risk factors. Blood. 2005;106:3358–3365
  35. Bassal M, Mertens AC, Taylor L, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: A report from the childhood cancer survivor study. J Clin Oncol. 2006;24:476–483
  36. Ries L, Kosary C, Hankey B, et al. SEER Cancer Statistics Review, 1973–1996. Bethesda, MD: National Cancer Institute; 1999;
  37. Ron E, Lubin J, Shore R, et al. Thyroid cancer after exposure to external radiation: A pooled analysis of seven studies. Radiat Res. 1995;141:259–277
  38. Sigurdson A, Ronckers C, Mertens A, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): A nested case-control study. Lancet. 2005;365:2014–2023
  39. Tucker M, Jones PH, Boice J, et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res. 1991;51:2885–2888
  40. Cardous-Ubbink M, Heinen R, Bakker P, et al. Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer. 2007;43:351–362
  41. Hodgson D, Gilbert E, Dores G, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25:1489–1497
  42. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol. 2004;22:2835–2841
  43. Donaldson S, Hancock S. Second cancers after Hodgkin's disease in childhood. N Eng J Med. 1996;334:792–794
  44. Josting A, Wiedenmann S, Franklin J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003;21:3440–3446
  45. Tucker M, Coleman C, Cox R, et al. Risk of second cancers after treatment for Hodgkin's disease. N Eng J Med. 1988;318:76–81
  46. Tucker MA, Meadows AT, Boice JD, et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst. 1987;78:459–464
  47. Breslow N, Takashima J, Whittam J, et al. Second malignant neoplasms following treatment for Wilms' tumor: A report from the Wilms' Tumor Study Group. J Clin Oncol. 1995;13:1851–1859
  48. Travis L, Hill D, Dores G, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290:465–475
  49. van Leeuwen F, Klokman W, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Nat Cancer Inst. 2003;95:971–980
  50. Forrest D, Hogge D, Nevill T, et al. High-dose therapy and autologous hematopoetic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol. 2005;23:7994–8002
  51. Koletsky A, Bertion J, Farber L, et al. Second neoplasms in patients with Hodgkin's disease following combined modality therapy—the Yale experience. J Clin Oncol. 1986;4:311–317
  52. Dietrich PY, Henry-Amar M, Cosset J, et al. Second primary cancers in patients continuously disease-free from Hodgkin's disease: A protective role for the spleen?. Blood. 1994;84:1209–1215
  53. Ng A, Bernardo M, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101–2108
  54. Donaldson SS, Glatstein E, Rosenberg SA, et al. Pediatric Hodgkin's disease. II. Results of therapy. Cancer. 1976;37:2436–2447
  55. Mertens A, Mitby P, Radloff G, et al. XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease: A report from the Childhood Cancer Survivor Study. Cancer. 2004;101:1463–1472

 Conflict of interest: none.

PII: S0360-3016(08)00839-0

doi: 10.1016/j.ijrobp.2008.04.067

International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 1 , Pages 24-33 , 1 September 2008

Article Tools

* Image Usage & Resolution